Previous close | 0.0022 |
Open | 0.0022 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0022 - 0.0022 |
52-week range | 0.0001 - 0.0271 |
Volume | |
Avg. volume | 833 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 08 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.
In this article, we look at 40 cities with the lowest life expectancy in the US. You can skip our section on developments in the pharmaceutical and biotech industries to enhance longevity and head over directly to 10 Cities with the Lowest Life Expectancy in the US. Average lifespan in the US climbed from just […]
Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).